Dr. Pawan Kumar Singh
Group Director, Hemato-Oncology & BMT
Centre For Bone Marrow Transplant
Dr. Pawan Kumar Singh is a leading name when it comes to Bone Marrow Transplant in India. He has been widely acknowledged for his versatile and patient-centric approach.
- Dr Singh has the experience of performing more than 1000 bone marrow transplants (including Autologous/Allogenic/Haplo/MUD) for both malignant and non-malignant disorders.
- Dr. Singh is successfully running the centre of excellence for HSCT programme for auto-immune diseases at Yatharth Group of Hospitals, especially Multiple Sclerosis and Systemic Sclerosis, CIDP, Myasthenia gravis, NMO.
Area Of Interest And Expertise
- Experience in performing complicated transplants like BMT in HIV and Hepatitis virus infected patients, Bloodless BMT in Jehovah witness cases, BMT in patients on dialysis simultaneous BMT in 2 recipient from single donor and many more.
- BMT in Thalassemia and Sickle Cell Disease.
- Induction therapy in Acute leukemia , MDS , Myeloma.
- Targeted therapy , Immuno therapy , Cancer diagnosis.
- CAR-T Cell Therapy.
Qualification
- MBBS
- MD (Internal Medicine)
- DM (Haematology)
Membership
- Indian Society of Haematology & Blood Transfusion.
- European Haematology Association.
Experience
Presently working as Group Director, Hemato-Oncology & BMT – Centre for Bone Marrow Transplant at Yatharth Group of Hospital, Noida Extension, Greater Noida, Noida sector 110, Faridabad.
Dr Pawan Kumar Singh is a renowned Haemato Oncologist & Bone Marrow Transplant specialist. He completed his DM in Haematology from the prestigious All India Institute of Medical Sciences, Delhi and brings with him an experience of more than 20+ years. He also worked in hematology department of CMC Vellore which is the first centre in india to start hematology training. He has experience of performing highest number of HSCT in Autoimmune Diseases especially Multiple Sclerosis and has performed more than 1000 BMTs including MSD, MUD and Haplo in adults and paediatric patients.
He also actively participates in research work and has authored various articles in both national and international publications.
Previous Experience:
- Senior Consultant and Head of Department - Hemato-oncology and BMT at Artemis Hospital, Gurgaon
- Associate Consultant - Department of Haemato-oncology and BMT at Jaypee Hospital, Noida
- Senior Resident - Department of Haematology at All India Institute of Medical Sciences, New Delhi
- Senior Registrar - Department of Haematology at Christian Medical College, Vellore
Frequently Asked Questions
A marrow transplant, also known as a hematopoietic stem cell transplant, involves the infusion of healthy blood-forming stem cells to replace damaged or diseased bone marrow.
Marrow transplants are considered the best option when other treatments have failed or when a patient’s condition requires the replacement of damaged or non-functioning bone marrow. It offers the possibility of long-term remission or cure for certain blood disorders.
There are two main types of marrow transplants: autologous, where a patient’s own stem cells are used, and allogeneic, where stem cells from a donor (usually a family member or unrelated donor) are used. The choice of transplant type depends on the patient’s diagnosis and other factors.
Principle of Autologous But : Two principles are
For malignant diseases : high dose chemotherapy is given followed by autologous Steam cell rescue to restore hematologists.
For autoimmune diseases : strong immuno suppression is done
chemo-immunotherapy for reselling the immune system and then
the new immune system comes in, which is not auto-reactive.
Finding a suitable donor involves matching human leukocyte antigens (HLA), which are proteins on the surface of WBC and other nucleated cells. Family members are often the first choice, but unrelated donors can be found through national and international registries. The best match increases the chances of transplant success.
Success rates vary depending on factors such as the type of transplant, the underlying condition, the patient’s age, and overall health. Allogeneic transplants may have a higher risk of complications but offer the potential for a cure. Autologous transplants may have a lower risk of complications but is indicated in certain cases.
From the date of infusion of stem cells , donor cells start to work between 10-20 days depending on the type of transplant and stem cell source. It may take several months to a year or more to fully recover and return to normal activities. Follow-up care is crucial for monitoring long-term effects and preventing complications.
Principle of Allogenic BMT: Two principles are
For malignant diseases : also called the GVL / GVT (Graft versus leukemia / Tumor effect). In this the patient is given new immune system after conditioning chemotherapy and the new immune system of donor wil forget against the cancer cells throughout life.
For decificent : In this the deficient blood system (ganetic / acquired) is corrected by replacing it with donor’s hematopoietic stem cells.
Best Doctor for BMT
Get Opinion from the expert for most effective treatment approach